Verdict Medical Devices

MHRA approves trofolastat for prostate cancer diagnostic imaging

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting cancerous lesions in men with prostate cancer. The post MHRA approves trofolastat for prostate cancer diagnostic imaging appeared first on Medical Device Network.

Mar 28, 2025 - 18:30
 0
MHRA approves trofolastat for prostate cancer diagnostic imaging
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for trofolastat (RoTecPSMA), a prostate-specific membrane antigen (PSMA)-targeting agent for detecting cancerous lesions in men with prostate cancer.

The post MHRA approves trofolastat for prostate cancer diagnostic imaging appeared first on Medical Device Network.

Read More

Tags:

Previous Article

Sigrid’s Carb Fence tech targets patients being left behind by GLP1s

Next Article

The best foods for healthy ageing ― and the worst

Related Posts

FDA grants 510(k) clearance for Huntleigh’s CTG Analysis

FDA grants 510(k) clearance for Huntleigh’s CTG Analysis

Mar 25, 2025  0

GE HealthCare delivers first PET MPI agent doses for CAD detection

GE HealthCare delivers first PET MPI agent doses for CA...

Feb 26, 2025  0

Foresight announces trial launch for cHL treatment with ctDNA-based MRD test

Foresight announces trial launch for cHL treatment with...

Mar 6, 2025  0